Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biol Blood Marrow Transplant ; 20(4): 490-4, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24361912

ABSTRACT

Washing cord blood (CB) grafts involves product manipulation and may result in cell loss. We investigated double-unit CB transplantation (CBT) using red blood cell (RBC)-depleted units diluted with albumin-dextran in patients with hematologic malignancies. One-hundred thirty-six patients (median age, 43 years; range, 4 to 71; median weight, 69 kilograms (kg); range, 24 to 111) underwent transplantation with a 4/6 to 6/6 HLA-matched graft. Patients ≤ 20 kg were excluded, as they only received washed units. Units were diluted a median of 8 fold to a median volume of 200 mL/unit. The median infused total nucleated cell doses were 2.7 (larger unit) and 2.0 (smaller unit) x 10(7)/kg, respectively, and the median post-thaw recovery was 86%. Units were infused consecutively (median, 45 minutes/unit). While only 17 patients (13%) had no infusion reactions, reactions in the remaining 119 patients were almost exclusively mild-moderate (by CTCAE v4 criteria 12 grade 1, 43 grade 2, 63 grade 3) with only 1 patient (< 1%) having a severe (grade 4) reaction. Moreover, most were easily treated. Grade 2 to 3 hypertension was the most common in 101 (74%) patients. The cumulative incidence of sustained donor-derived neutrophil engraftment was high: 95% in myeloablative and 94% in nonmyeloablative CBT recipients. With appropriate supportive care, double-unit CBT with RBC-depleted grafts infused after albumin-dextran dilution is safe with high rates of engraftment in patients > 20 kg.


Subject(s)
Cord Blood Stem Cell Transplantation/methods , Graft Survival , Hematologic Neoplasms/therapy , Transplantation Conditioning , Adolescent , Adult , Aged , Child , Child, Preschool , Dextrans/administration & dosage , Female , HLA Antigens/immunology , Hematologic Neoplasms/immunology , Hematologic Neoplasms/pathology , Histocompatibility Testing , Humans , Male , Middle Aged , Myeloablative Agonists/therapeutic use , Pharmaceutical Vehicles/administration & dosage , Retrospective Studies , Serum Albumin/administration & dosage , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...